The WIN Consortium, supported by its media partner Nature Publishing Group, has opened registration for the second annual WIN Symposium, to be held in the Palais des Congrès, Paris, on the 7th to 9th of July 2010. The WIN Symposium is an open and interactive forum designed to promote rapid translation of ground-breaking personalized cancer medicine discoveries to clinical practice. This innovative meeting has received the endorsement of major oncology organizations around the world, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Organisation of European Cancer Institutes (OECI). The WIN Consortium is a joint initiative of the Institut Gustave Roussy (France) and The University of Texas M. D. Anderson Cancer Center (USA), in association with several other leading cancer care institutions in Europe, the United States of America, Canada, and Asia.
“More than 10 million people around the world develop cancer every year”
“We are very pleased to receive the endorsement of these prestigious oncology organizations, guaranteeing the high quality of the WIN Symposium’s scientific content,” said Dr Vladimir Lazar, Co-ordinator of the WIN Consortium and Head of Functional Genomics at the Institut Gustave Roussy.
“These endorsements acknowledge that early diagnosis and personalized treatments are the most efficient approaches to improving the outcomes of cancer and significantly decreasing global mortality rates,” said John Mendelsohn, M.D., President, The University of Texas M. D. Anderson Cancer Center.
“More than 10 million people around the world develop cancer every year,” commented Professor David Kerr, ESMO President. “Early diagnosis and a tailored program of therapy are the best ways to improve the outcome for these patients. In recognition of its efforts, ESMO is pleased to certify the WIN Symposium with 17 ESMO-MORA category 1 points, enabling participants to collect CME.”
“Endorsement of the WIN Symposium is part of our commitment to further expanding the scope of ASCO’s international programs, with the overarching goal of improving cancer care on a global level,” added Douglas Pyle, ASCO Senior Director of International Affairs.
“The pursuit of knowledge and the reduction of fragmentation in oncology research are instrumental to finding new and better cancer treatments. A holistic approach, as promoted by initiatives such as the WIN Consortium, is the only way to provide more comprehensive care and improve the quality of life for patients,” concluded Dr Marco Pierotti, OECI President.
By promoting closer collaboration between academia and industry, the WIN Consortium is helping to accelerate new technologies from the bench to the bedside, and has received worldwide acknowledgment from academia, as well as the backing of influential technology providers such as Agilent Technologies, GE Healthcare and Life Technologies. The program of the Symposium is dedicated to personalized medicine and the future of oncology care, and will be presented by key opinion leaders in the field, including:
Cleveland Clinic presents new findings on triple-negative breast cancer vaccine